The USFDA has approved plasminogen human tmvh for the treatment of plasminogen deficiency type 1. The active ingredient in this treatment is plasminogen, which is extracted from human plasma and helps to raise plasminogen levels in the blood. The treatment resulted in more than 50% improvement in lesions and the absence of recurrent lesions This treatment has been approved for patients with plasminogen deficiency type 1 , commonly known as hypoplasminogenemia , a condition that can impede normal tissue and organ function and lead to blindness .
This disease is caused by a deficiency in the protein plasminogen, which is responsible for the body's capacity to break down fibrin clots. Plasminogen deficiency causes fibrin to accumulate, resulting in the formation of lesions that can compromise normal tissue and organ function and, in the case of the eyes, can lead to blindness. The active…
